IL136230A0 - An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes - Google Patents

An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes

Info

Publication number
IL136230A0
IL136230A0 IL13623098A IL13623098A IL136230A0 IL 136230 A0 IL136230 A0 IL 136230A0 IL 13623098 A IL13623098 A IL 13623098A IL 13623098 A IL13623098 A IL 13623098A IL 136230 A0 IL136230 A0 IL 136230A0
Authority
IL
Israel
Prior art keywords
mutant
protein
preparation
pharmaceutical purposes
active hedgehog
Prior art date
Application number
IL13623098A
Other languages
English (en)
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97120891A external-priority patent/EP0919618A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of IL136230A0 publication Critical patent/IL136230A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13623098A 1997-11-28 1998-11-23 An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes IL136230A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97120891A EP0919618A1 (de) 1997-11-28 1997-11-28 Aktive Hedgehog-Protein-Mutante, Verfahren zur Herstellung und Verwendung
EP98102095 1998-02-06
PCT/EP1998/007557 WO1999028454A1 (en) 1997-11-28 1998-11-23 An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes

Publications (1)

Publication Number Publication Date
IL136230A0 true IL136230A0 (en) 2001-05-20

Family

ID=26145926

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13623098A IL136230A0 (en) 1997-11-28 1998-11-23 An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
IL136230A IL136230A (en) 1997-11-28 2000-05-18 Active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL136230A IL136230A (en) 1997-11-28 2000-05-18 Active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes

Country Status (8)

Country Link
US (3) US6994990B1 (ja)
EP (1) EP1034269A1 (ja)
JP (1) JP2001525341A (ja)
AU (1) AU752816B2 (ja)
CA (1) CA2312009A1 (ja)
IL (2) IL136230A0 (ja)
MA (1) MA26570A1 (ja)
WO (1) WO1999028454A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136230A0 (en) * 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
DK0953576T3 (da) * 1998-04-30 2006-03-20 Curis Inc Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148901A (en) * 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5409611A (en) * 1988-03-24 1995-04-25 Terrapin Technoogies, Inc. Method to identify analyte-binding ligands
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5156623A (en) * 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
WO1993000050A1 (en) 1991-06-21 1993-01-07 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US6610656B1 (en) * 1993-12-30 2003-08-26 President And Fellows Of Harvard College Method of promoting chondrocyte differentiation with hedgehog related polypeptides
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
PT733109E (pt) 1993-12-07 2006-07-31 Genetics Inst Llc Proteinas morfogeneticas dos 0ss0s pmo-12 e pmo-13 e as suas composicoes para inducao de tendao
US6884775B1 (en) * 1993-12-30 2005-04-26 President And Fellows Of Harvard College Methods and compositions for regulating skeletogenic formation
US6261786B1 (en) * 1993-12-30 2001-07-17 Imperial Cancer Res. Technology Screening assays for hedgehog agonists and antagonists
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
US7060450B1 (en) * 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
US20030186357A1 (en) * 1993-12-30 2003-10-02 Philip W. Ingham Vertebrate embryonic pattern-inducing proteins, and uses related thereto
US6384192B1 (en) * 1993-12-30 2002-05-07 President & Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US5700774A (en) 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
JP2002503088A (ja) 1996-10-07 2002-01-29 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 新規ヘッジホッグ由来ポリペプチド
IL136230A0 (en) * 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
EA003739B1 (ru) * 1997-12-03 2003-08-28 Байоджен, Инк. Гидрофобно-модифицированные белки, способы их получения и их применение
DK0953576T3 (da) * 1998-04-30 2006-03-20 Curis Inc Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse
DK0978285T3 (da) * 1998-08-07 2006-03-27 Curis Inc Stabilt farmaceutisk præparat af hedgehogproteiner og anvendelse deraf
CA2348773C (en) * 1998-11-02 2010-04-13 Biogen, Inc. Functional antagonists of hedgehog activity
EP1183271A1 (en) * 1999-06-01 2002-03-06 Biogen, Inc. Polymer conjugates of hedgehog proteins and uses
AU2001255767A1 (en) * 2000-04-28 2001-11-12 Curis, Inc. Methods and reagents for tissue engineering of cartilage in vitro

Also Published As

Publication number Publication date
WO1999028454A1 (en) 1999-06-10
AU1757099A (en) 1999-06-16
US20060073566A1 (en) 2006-04-06
MA26570A1 (fr) 2004-12-20
US20040138130A1 (en) 2004-07-15
EP1034269A1 (en) 2000-09-13
US6994990B1 (en) 2006-02-07
AU752816B2 (en) 2002-10-03
JP2001525341A (ja) 2001-12-11
CA2312009A1 (en) 1999-06-10
IL136230A (en) 2007-08-19

Similar Documents

Publication Publication Date Title
GR970300037T1 (en) Phenol-derivatives having pharmaceutical activity and process for preparing the same
PL320856A1 (en) Aerosol drug preparations
EP0645136A3 (en) Pharmaceutical preparation of the type: physiologically active substance with sustained release.
HK1020956A1 (en) Oxadiazoles, processes for their preparation and their use as medicaments
HUP0100900A3 (en) Pharmaceutically active morpholinol and medicaments containing them
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
ZA982872B (en) Pharmaceutical formulation
HK1020949A1 (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
ZA967546B (en) Pharmaceutical formulation.
IL136425A0 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
HK1019606A1 (en) Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
HRP980258B1 (en) New triazole derivatives, process for the preparation thereof and pharmaceutical preparations containing them
ZA96960B (en) Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz[b,f]oxepines
CZ2000522A3 (cs) Farmaceutický prostředek na bázi piperidinalkanolového antihistaminika a použití
ZA982073B (en) Pharmaceutical preparation
EP1002793A4 (en) PHYSIOLOGICALLY ACTIVE SUBSTANCES TKR2449, METHOD FOR THEIR PRODUCTION AND MICROORGANISMS
HUP9600665A3 (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
IL135520A0 (en) 8-azabicyclo [3.2.1.] octane-3-methanamine derivatives, their preparation and their therapeutic application
HK1015763A1 (en) Benzoxazindione derivatives, process for their preparation and their use
IL136230A0 (en) An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
HUP0004661A3 (en) Polyhydroxybutylpyrazines, their preparation and medicines containing them
ZA9810403B (en) New epothilon derivatives, process for their preparation and their pharmaceutical use.
HUP0103569A3 (en) New medicament and process for its preparation
ZA9810846B (en) An active hedgehog-protein-mutant a process for its preparation and its use for pharmaceutical purposes

Legal Events

Date Code Title Description
FF Patent granted
KB20 Patent renewed for 20 years